keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28933270/11c-choline-pet-ct-based-helical-tomotherapy-as-treatment-approach-for-bone-metastases-in-recurrent-prostate-cancer-patients
#1
Elena Incerti, Vincenzo Gangemi, Paola Mapelli, Chiara Lucrezia Deantoni, Giampiero Giovacchini, Federico Fallanca, Andrei Fodor, Andrea Ciarmiello, Sergio Baldari, Luigi Gianolli, Nadia Di Muzio, Maria Picchio
To evaluate the efficacy of 11C-choline PET/CT (CHO-PET/CT) based helical tomotherapy (HTT) as a therapeutic approach for bone metastases in recurrent prostate cancer (PCa) patients. METHODS This retrospective study includes 20 PCa patients (median age: 67; range: 51-80 years) presenting biochemical relapse after primary treatment who underwent CHO-PET/CT based HTT on positive bone metastases from December 2007 to June 2014. The effectiveness of HTT assessed with biochemical response at 3/6/12 months, biochemical relapse free survival (bRFS) and overall survival (OS) at 2 years...
September 19, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28929350/optimal-mri-sequences-for-68-ga-psma-11-pet-mri-in-evaluation-of-biochemically-recurrent-prostate-cancer
#2
Spencer T Lake, Kirsten L Greene, Antonio C Westphalen, Spencer C Behr, Ronald Zagoria, Eric J Small, Peter R Carroll, Thomas A Hope
BACKGROUND: PET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged with (68)Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive findings on (68)Ga-PSMA-11 PET of patients with BCR after definitive therapy. Fifty-five consecutive prostate cancer patients with BCR imaged with (68)Ga-PSMA-11 3.0T PET/MRI were retrospectively analyzed. Mean PSA was 7.9 ± 12.9 ng/ml, and mean PSA doubling time was 7...
September 19, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28927782/development-and-internal-validation-of-prediction-models-for-biochemical-failure-and-composite-failure-after-focal-salvage-high-intensity-focused-ultrasound-for-local-radiorecurrent-prostate-cancer-presentation-of-risk-scores-for-individual-patient-prognoses
#3
Max Peters, Abi Kanthabalan, Taimur T Shah, Neil McCartan, Caroline M Moore, Manit Arya, Jochem R van der Voort van Zyp, Marinus A Moerland, Richard G Hindley, Mark Emberton, Hashim U Ahmed
PURPOSE: Patient selection for focal salvage remains difficult. Therefore, we developed and internally validated prediction models for biochemical failure (BF) and a composite endpoint (CE) following focal salvage high intensity focused ultrasound (HIFU) for radiorecurrent prostate cancer. MATERIALS AND METHODS: A prospective HIFU registry identified 150 cases (November 2006-August 2015). Recurrence was assessed with multiparametric magnetic resonance imaging (MRI) combined with template prostate mapping biopsies, targeted biopsies, or systematic transrectal ultrasound-guided biopsies...
September 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28924629/a-psma-ligand-labeled-with-cobalt-55-for-pet-imaging-of-prostate-cancer
#4
Johan Hygum Dam, Birgitte Brinkmann Olsen, Christina Baun, Poul Flemming Høilund-Carlsen, Helge Thisgaard
PURPOSE: Prostate-specific membrane antigen (PSMA) comprises a recognized target for molecular imaging of prostate cancer. As such, radiolabeled PSMA inhibitors are of great value for diagnosis and staging of this disease. Herein, we disclose the preclinical characterization of [(55)Co]PSMA-617 for positron emission tomography (PET)/x-ray computed tomography (CT) imaging of prostate cancer lesions. PROCEDURES: By the application of microwave heating, PSMA-617 in acetate buffer (0...
September 18, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28922335/the-role-of-68ga-psma-i-t-pet-ct-in-the-pretreatment-staging-of-primary-prostate-cancer
#5
Danielle P Meyrick, Marcus Asokendaran, Laura A Skelly, Nat P Lenzo, Andrew Henderson
OBJECTIVES: This retrospective study aimed to evaluate the role of Ga-PSMA-I&T PET/CT in the primary staging of newly diagnosed prostate cancer (PCa), with a focus on the detection of metastatic nodal disease. Correlation of the rate of detection of metastatic disease by Ga-PSMA-I&T PET/CT with the Gleason score (GS) and serum prostate-specific antigen (PSA) was performed to determine the GS and PSA criteria defining patients who would benefit from Ga-PSMA-I&T PET/CT imaging for staging, risk stratification and therapy optimization...
September 15, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28916273/identification-of-recurrence-sites-following-post-prostatectomy-treatment-for-prostate-cancer-using-11-c-choline-positron-emission-tomography-and-multiparametric-pelvic-mri
#6
Avinash Nehra, William P Parker, Rimki Haloi, Sean S Park, Lance A Mynderse, Val J Lowe, Brian J Davis, J Fernando Quevedo, Geoffrey B Johnson, Eugene D Kwon, R Jeffrey Karnes
PURPOSE: To describe anatomic sites of recurrence among prostate cancer patients with biochemical recurrence following radical prostatectomy (RP) and postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT) using (11)C-Choline PET/CT and multiparametric-MRI. MATERIALS AND METHODS: RP patients evaluated with (11)C-Choline PET/CT and multiparametric-MRI following RT and/or ADT were evaluated for patterns of recurrence and clinicopathologic features...
September 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28912144/androgen-and-estrogen-receptor-imaging-in-metastatic-breast-cancer-patients-as-a-surrogate-for-tissue-biopsies
#7
Clasina M Venema, Lemonitsa H Mammatas, Carolina P Schröder, Michel van Kruchten, Giulia Apollonio, Andor W J M Glaudemans, A H H Bongaerts, Otto S Hoekstra, Henk M W Verheul, Epie Boven, Bert van der Vegt, Erik F de Vries, Elisabeth G E de Vries, Ronald Boellaard, Catharina Willemien Menke-van der Houven van Oordt, Geke Ap Hospers
In addition to the well-known estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2), the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole body imaging can provide information across lesions within a patient. ER expression in tumor lesions can be visualized by (18)F-fluoroestradiol (FES) PET, and AR expression has been visualized in prostate cancer patients with (18)F-fluorodihydrotestosterone (FDHT) PET. Our aim was to assess the concordance between FDHT- and FES-PET and tumor AR- and ER-expression measured immunohistochemically (IHC) in patients with metastatic breast cancer...
September 14, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28910151/synthesis-positron-emission-tomography-imaging-and-therapy-of-diabody-targeted-drug-lipid-nanoparticles-in-a-prostate-cancer-murine-model
#8
Patty Wong, Lin Li, Junie Chea, Melissa K Delgado, Erasmus Poku, Barbara Szpikowska, Nicole Bowles, Megan Minnix, David Colcher, Jeffrey Y C Wong, John E Shively, Paul J Yazaki
The blood clearance of chemotherapeutic drugs such as doxorubicin (Dox) can be extended by incorporation into lipid nanoparticles (LNPs) and further improved by tumor targeting with antibody fragments. We used positron emission tomography (PET) imaging in a murine prostate cancer model to evaluate tumor targeting of LNPs incorporating Dox and antiprostate-specific membrane antigen (PSMA) diabodies. Dox-LNPs were generated by mixing or covalent attachment to water soluble distearoylphosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG)2000...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28903405/uptake-of-psma-ligands-in-normal-tissues-is-dependent-on-tumor-load-in-patients-with-prostate-cancer
#9
Florian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A Bundschuh, Holger Strunk, Markus Essler
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902738/false-positive-pancreatic-uptake-detected-on-68ga-psma-pet-ct-a-priority-changing-incidental-finding-while-assessing-the-need-for-a-prostate-biopsy
#10
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Alan Alper Sag, Yersu Kapran
A 72-year-old man underwent Ga-PSMA PET/CT because of an elevated prostate-specific antigen level despite prior prostatectomy. Besides low-intensity prostatic PSMA reactivities, a faintly PSMA-positive lesion in the pancreatic corpus drew attention, which seemed suggestive of a primary pancreatic cancer on the subsequent MRI and therefore had to be excised. The final diagnosis was pT3 low-grade neuroendocrine tumor. PSMA-positive incidentalomas, detected on Ga-PSMA PET/CT, can reveal more clinically significant extraprostatic disorders...
September 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28902734/incidental-detection-of-hepatocellular-carcinoma-on-68ga-labeled-prostate-specific-membrane-antigen-pet-ct
#11
D Patel, H Loh, K Le, A Stevanovic, R Mansberg
A 66-year-old man with history of prostate carcinoma underwent Ga-labeled prostate-specific membrane antigen PET/CT for surveillance of rising prostate-specific antigen. Intense tracer uptake was noted in segments 2, 7, and 8 of the liver. The lesions were not FDG avid on F-FDG PET/CT. Further characterization with magnetic resonance cholangiopancreatography with Gd-EOB (Primovist) contrast revealed ill-defined arterially enhancing lesions with central washout in the venous phase. CT-guided core biopsy was performed, and histopathology confirmed well-differentiated hepatocellular carcinoma...
September 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28900854/relationships-between-serum-psa-levels-gleason-scores-and-results-of-68ga-psmapet-ct-in-patients-with-recurrent-prostate-cancer
#12
Yasemin Sanli, Serkan Kuyumcu, Oner Sanli, Fikret Buyukkaya, Ayça İribaş, Goksel Alcin, Emin Darendeliler, Yasemin Ozluk, Sevda Ozel Yildiz, Cüneyt Turkmen
AIM: To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga(68)-PSMA PET/CT in patients with recurrent PCa. METHODS: A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented...
September 12, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28894899/clinical-impact-of-psma-based-18-f-dcfbc-pet-ct-imaging-in-patients-with-biochemically-recurrent-prostate-cancer-after-primary-local-therapy
#13
Esther Mena, Maria L Lindenberg, Joanna H Shih, Stephen Adler, Stephanie Harmon, Ethan Bergvall, Deborah Citrin, William Dahut, Anita T Ton, Yolanda McKinney, Juanita Weaver, Philip Eclarinal, Alicia Forest, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Peter Pinto, Bradford J Wood, Paula Jacobs, Martin G Pomper, Peter L Choyke, Baris Turkbey
PURPOSE: The purpose of our study was to assess (18)F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. METHODS: This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging...
September 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28891271/solubility-improved-10-o-substituted-sn-38-derivatives-with-antitumor-activity
#14
Hisashi Doi, Tatsuya Kida, Kosuke Nishino, Masatoshi Nakatsuji, Shiho Sakamoto, Shota Shimizu, Yoshiaki Teraoka, Yasuhisa Tamura, Yosky Kataoka, Takashi Inui
With the objective of improving the poor water solubility of the potent antitumor compound SN-38, 10-O-substituted SN-38 derivatives were developed by the introduction of fluoroalkyl, fluorobenzoyl, or bromobenzoyl groups. The 10-O-fluoropropyl-substituted compound 2 (RLC140050) was found to be 17-fold more soluble than SN-38 in phosphate buffered saline, and it exhibited a level of biological activity ~50% that of SN-38 in a cytotoxicity assay using the prostate cancer cell line PC-3. Five other derivatives did not show solubility improvement to the same extent, but their activities in cytotoxicity assays were almost the same as that of SN-38...
September 11, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28891033/targeted-alpha-therapy-of-mcrpc-dosimetry-estimate-of-213-bismuth-psma-617
#15
Clemens Kratochwil, Karl Schmidt, Ali Afshar-Oromieh, Frank Bruchertseifer, Hendrik Rathke, Alfred Morgenstern, Uwe Haberkorn, Frederik L Giesel
PURPOSE: PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA). In this work, we estimate the radiation dosimetry for this ligand labeled with the alpha-emitter (213)Bi. METHODS: Three patients with metastatic prostate cancer underwent PET scans 0.1 h, 1 h, 2 h, 3 h, 4 h and 5 h after injection of (68)Ga-PSMA-617. Source organs were kidneys, liver, spleen, salivary glands, bladder, red marrow and representative tumor lesions...
September 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28890087/-therapeutic-innovations-in-radiation-oncology-for-localized-prostate-cancer
#16
G Créhange, L Cormier
Intensity-modulated radiation therapy, image-guided radiation therapy with fiducial markers and prostate brachytherapy allow the delivery of dose escalation for localized prostate cancer with very low rates of long-term toxicity and sequelae. Nowadays, modern radiotherapy techniques make it possible to shorten treatment time with hypofractionation, to better protect surrounding healthy tissues and to escalate the dose even further. Advances in radiotherapy are closely linked to advances in magnetic resonance imaging (MRI) and/or PET imaging...
September 7, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28889366/performance-of-68-ga-psma-pet-ct-for-prostate-cancer-management-at-initial-staging-and-time-of-biochemical-recurrence
#17
REVIEW
Jason Bailey, Morand Piert
PURPOSE OF THE REVIEW: Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ((68)Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. RECENT FINDINGS: (68)Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, (68)Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that (68)Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL)...
September 9, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28887401/proposal-of-a-structured-reporting-system-for-prostate-specific-membrane-antigen-psma-targeted-pet-imaging-psma-rads-version-1-0
#18
Steven Rowe, Kenneth Pienta, Martin G Pomper, Michael Gorin
As medical imaging has grown progressively more complicated and sub-specialized in recent decades, a number of standardized reporting systems have been proposed for a variety of imaging modalities and conditions. These include reporting and data systems for imaging of the breast (BI-RADS) (1), prostate (PI-RADS) (2), lung (LUNG-RADS) (3), liver (LI-RADS) (4), and thyroid (TI-RADS) (5). While these systems differ extensively in their details, each provides a standardized framework for conveying findings and recommendations to clinicians...
September 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28887398/-64-cucl2-pet-ct-in-prostate-cancer-relapse
#19
Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria
To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated...
September 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28878857/unusual-soft-tissue-uptake-of-f-18-sodium-fluoride-in-three-patients-undergoing-f-18-naf-pet-ct-bone-scans-for-prostate-cancer
#20
Andrew S Hawkins, Brandon A Howard
Three males aged 71 to 80 years with known stage IV metastatic prostate cancer underwent F-18 sodium fluoride (NaF) PET/CT to assess osseous metastatic disease burden and stability. In addition to F-18 NaF avid known osseous metastases, each patient also exhibited increased F-18 NaF activity in soft tissues. The first patient exhibited multiple F-18 NaF avid enlarged retroperitoneal and pelvic lymph nodes on consecutive PET/CT scans. The second patient demonstrated an F-18 NaF avid thyroid nodule on consecutive PET/CT scans...
September 2017: Nuclear Medicine and Molecular Imaging
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"